B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout”
B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout”
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Essa Pharma (EPIX), 7,060% surge in interest Chromadex (CDXC),
Jefferies analyst Akash Tewari maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target of $400.00. The company’s shares closed last Friday at
Shares of companies developing therapies for the liver disease metabolic steatohepatitis, or MASH, are rallying after Novo Nordisk (NVO) said its GLP-1 drug semaglutide showed “superior improvement” in treating the
In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target of $360.00. The company’s shares